Uluru Inc. (ULUR)
Stock Price:
$0.5100 USD
0.0000 (0.00%)
Updated November 27, 9:30 AM EST - Market closed
Key Info
| Market Cap |
10.27M |
| Revenue (ttm) |
568,744 |
| Net Income (ttm) |
-2.20M |
| Shares Out |
20.14M |
| EPS (ttm) |
-0.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$0.5100 |
| Previous Close |
$0.5100 |
| Change ($) |
0.0000 |
| Change (%) |
0.00% |
| Day's Open |
0.5100 |
| Day's Range |
0.5100 - 0.5100 |
| Day's Volume |
0 |
| 52-Week Range |
0.0011 - 1.1 |
More Stats
| Market Cap |
10.27M |
| Enterprise Value |
8.29M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
20.14M |
| Float |
17.08M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.11 |
| FCF / Share |
-0.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2,034 |
| Short Ratio |
0.08 |
| Short % of Float |
0.01% |
| Beta |
-2.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
18.06 |
| PB Ratio |
2.37 |
| Revenue |
568,744 |
| Operating Income |
-1.80M |
| Net Income |
-2.20M |
| Free Cash Flow |
-1.79M |
| Net Cash |
1.98M |
| Net Cash / Share |
0.10 |
| Gross Margin |
85.71% |
| Operating Margin |
-316.94% |
| Profit Margin |
-387.30% |
| FCF Margin |
-314.90% |
| ROA |
-13.86% |
| ROE |
-40.65% |
| ROIC |
334.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
1,200
Current: $0.5100
High
1,200
Target: 1,200
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|
| Revenue | 0.72 | 0.44 | 0.94 | 0.86 | 0.37 | 0.37 | 0.48 | 1.56 | 0.67 | 0.73 |
| Revenue Growth | 62.05% | -52.7% | 8.32% | 133.12% | -0.01% | -23.52% | -68.89% | 133.16% | -8.93% | - |
| Gross Profit | 0.49 | 0.41 | 0.66 | 0.35 | 0.15 | 0.13 | 0.28 | 1.40 | 0.63 | 0.59 |
| Operating Income | -1.74 | -4.30 | -2.44 | -1.70 | -2.64 | -3.26 | -4.01 | -4.14 | -8.53 | -10.10 |
| Net Income | -1.94 | -4.45 | -2.70 | -1.94 | -3.08 | -3.53 | -4.07 | -5.03 | -9.23 | -9.78 |
| Shares Outstanding | 125 | 56.68 | 25.90 | 23.64 | 14.77 | 8.49 | 6.07 | 5.44 | 4.48 | 4.25 |
| Earnings Per Share | -0.02 | -0.08 | -0.10 | -0.08 | -0.21 | -0.42 | -0.67 | -0.93 | -2.10 | -2.25 |
| Operating Cash Flow | -2.20 | -1.56 | -2.08 | -1.06 | -1.73 | -0.96 | -1.69 | -2.70 | -6.89 | -6.01 |
| Capital Expenditures | - | - | -0.01 | -0.03 | -0.03 | -0.06 | - | - | -0.01 | -0.45 |
| Free Cash Flow | -2.20 | -1.56 | -2.09 | -1.09 | -1.77 | -1.02 | -1.69 | -2.70 | -6.90 | -6.46 |
| Cash & Equivalents | 3.73 | 0.05 | 0.20 | 0.57 | 0.02 | 0.04 | 0.06 | 0.66 | 1.95 | 7.59 |
| Total Debt | 0.57 | 0.02 | 0.32 | - | 1.15 | 1.84 | 0.23 | - | - | - |
| Net Cash / Debt | 3.16 | 0.03 | -0.12 | 0.57 | -1.12 | -1.80 | -0.17 | 0.66 | 1.95 | 7.59 |
| Assets | 8.54 | 4.34 | 7.43 | 5.46 | 5.90 | 7.33 | 7.06 | 9.02 | 13.38 | 21.13 |
| Liabilities | 2.44 | 2.77 | 3.23 | 2.71 | 4.17 | 5.48 | 2.96 | 1.61 | 2.20 | 3.60 |
| Book Value | 6.11 | 1.57 | 4.20 | 2.75 | 1.73 | 1.85 | 4.10 | 7.41 | 11.18 | 17.53 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Uluru Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Vaidehi Shah |
Stock Information
| Ticker Symbol |
ULUR |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
OTCMKTS: ULUR |
Description
ULURU, a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. and is headquartered in Addison, Texas.